Ipsen SA

Ipsen appoints Keira Driansky as EVP, President of North America

02 May 2024 01:30:00 By Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

24 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

22 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Ipsen publishes its 2023 Universal Registration Document

17 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

08 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

02 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Mar 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

15 Feb 2024 04:00:45 By Nasdaq GlobeNewswire

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

13 Feb 2024 16:08:23 By Nasdaq GlobeNewswire

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

08 Feb 2024 00:58:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Feb 2024 12:00:00 By Nasdaq GlobeNewswire

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

22 Jan 2024 17:00:00 By Nasdaq GlobeNewswire

Ipsen – Half year statement – 2023 12 31

08 Jan 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

05 Jan 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Dec 2023 12:49:00 By Nasdaq GlobeNewswire

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

07 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

07 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023

14 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

13 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023

07 Nov 2023 12:00:00 By Nasdaq GlobeNewswire